DiscoverFrankly Speaking About Family MedicineThe Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399
The Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399

The Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399

Update: 2024-09-23
Share

Description

Credits: 0.25 AMA PRA Category 1 Credit™

 

CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-399


Overview: In this episode, we look at a new study showing increased probability of survival for patients with Alzheimer disease (AD) who take donepezil and memantine together. We review current treatments for AD and address common hesitations in prescribing dual pharmacotherapy, providing vital insights for primary care clinicians.


Episode resource links:


  • Yaghmaei, E., Lu, H., Ehwerhemuepha, L. et al. Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer’s disease patients.Commun Med 4, 99 (2024). https://doi.org/10.1038/s43856-024-00527-6

  • Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. PMID: 32914577; PMCID: PMC7667299.


Guest: Jillian Joseph, MPAS, PA-C


Music Credit: Matthew Bugos


Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com 


 

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

The Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399

The Dual Advantage: Improving Alzheimer Care with Combination Therapy - Frankly Speaking Ep 399

Pri-Med